biotech
biotech Articles
Aeglea BioTherapeutics expects to price more than 3 million shares in a range of $16 to $18 per share for an initial public offering valued up to more than $72 million.
Published:
Last Updated:
Apricus Biosciences announced top-line results from the Phase 2b proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual dysfunction.
Published:
Last Updated:
Alder Biopharmaceuticals announced positive top-line data from two clinical trials evaluating its proprietary monoclonal antibody product candidate for migraine prevention.
Published:
Last Updated:
Over the past week, Akorn, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
Published:
Last Updated:
With the quarter winding down, so to are the windows for insiders to make transactions before earnings are reported. We saw a definite volume drop this week.
Published:
Last Updated:
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Published:
Last Updated:
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Published:
Last Updated:
Akorn reported its preliminary 2015 financial results before the markets opened on Tuesday and issued guidance for the 2016 full year.
Published:
Last Updated:
Moleculin Biotech plans to list up to 2 million shares at an estimated $5.50 apiece in an IPO valued at up to $11 million.
Published:
Last Updated:
Clearside Biomedical has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
What are investors supposed to make of a Bank of America Merrill Lynch call that shows GW Pharmaceuticals worth over 100% more than the current value?
Published:
Last Updated:
Over the past week, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
Published:
Last Updated:
Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
Published:
Last Updated:
24/7 Wall St. has collected a few more U.S. Food and Drug Administration (FDA) decisions coming up in March.
Published:
Last Updated:
Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on the stock.
Published:
Last Updated: